TRML Projected Dividend Yield
Tourmaline Bio Inc ( NASDAQ : TRML )Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. Co. is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. Co.'s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. 21 YEAR PERFORMANCE RESULTS |
TRML Dividend History Detail TRML Dividend News TRML Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |